---
document_datetime: 2025-09-29 15:14:25
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/spikevax-previously-covid-19-vaccine-moderna-epar-all-authorised-presentations_en.pdf
document_name: spikevax-previously-covid-19-vaccine-moderna-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 5.3482363
conversion_datetime: 2025-12-19 02:01:20.636726
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name                           | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging                        | Content (concentration)   | Pack size                             |
|------------------|-------------------------------------------|------------|--------------------------|---------------------------|--------------------------------------------|---------------------------|---------------------------------------|
| EU/1/20/1507/001 | Spikevax                                  | --¹        | Dispersion for injection | Intramuscular use         | vial (glass or cyclic olefin polymer)      | 5 ml (10 or 20 doses)     | 10 multidose vials (100 or 200 doses) |
| EU/1/20/1507/002 | Spikevax                                  | --²        | Dispersion for injection | Intramuscular use         | vial (glass or cyclic olefin polymer)      | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses)  |
| EU/1/20/1507/003 | Spikevax                                  | --²        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin polymer) | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses)     |
| EU/1/20/1507/004 | Spikevax bivalent Original/Omicron BA.1   | --³        | Dispersion for injection | Intramuscular use         | vial (glass or cyclic olefin polymer)      | 5 ml (10 or 20 doses)     | 10 multidose vials (100 or 200 doses) |
| EU/1/20/1507/005 | Spikevax bivalent Original/Omicron BA.1   | --³        | Dispersion for injection | Intramuscular use         | vial (glass or cyclic olefin polymer)      | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses)  |
| EU/1/20/1507/006 | Spikevax bivalent Original/Omicron BA.4-5 | -- ⁴       | Dispersion for injection | Intramuscular use         | vial (glass or cyclic olefin polymer)      | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses)  |
| EU/1/20/1507/007 | Spikevax bivalent Original/Omicron BA.1   | --³        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin polymer) | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses)     |
| EU/1/20/1507/008 | Spikevax bivalent Original/Omicron BA.1   | --³        | Dispersion for injection | Intramuscular use         | vial (glass)                               | 0.5 ml (1 dose)           | 10 single dose vials (10 doses)       |
| EU/1/20/1507/009 | Spikevax bivalent Original/Omicron BA.4-5 | -- ⁴       | Dispersion for injection | Intramuscular use         | vial (glass)                               | 0.5 ml (1 dose)           | 10 single dose vials (10 doses)       |

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name                           | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging                                       | Content (concentration)   | Pack size                            |
|------------------|-------------------------------------------|------------|--------------------------|---------------------------|-----------------------------------------------------------|---------------------------|--------------------------------------|
| EU/1/20/1507/010 | Spikevax bivalent Original/Omicron BA.4-5 | -- ⁴       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin polymer)                | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses)    |
| EU/1/20/1507/011 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | vial (glass)                                              | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses) |
| EU/1/20/1507/012 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | vial (cyclic olefin polymer)                              | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses) |
| EU/1/20/1507/013 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | vial (glass)                                              | 0.5 ml (1 dose)           | 1 single dose vial (1 dose)          |
| EU/1/20/1507/014 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | vial (glass)                                              | 0.5 ml (1 dose)           | 10 single dose vials (10 doses)      |
| EU/1/20/1507/015 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a blister | 0.5 ml (1 dose)           | 1 pre-filled syringe (1 dose)        |
| EU/1/20/1507/016 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a blister | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses)    |
| EU/1/20/1507/017 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a tray    | 0.5 ml (1 dose)           | 1 pre-filled syringe (1 dose)        |
| EU/1/20/1507/018 | Spikevax XBB.1.5                          | -- 5       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a tray    | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses)    |

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging                                                 | Content (concentration)   | Pack size                            |
|------------------|-------------------|------------|--------------------------|---------------------------|---------------------------------------------------------------------|---------------------------|--------------------------------------|
| EU/1/20/1507/019 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | vial (glass)                                                        | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses) |
| EU/1/20/1507/020 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | vial (cyclic olefin polymer)                                        | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses) |
| EU/1/20/1507/021 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | vial (glass)                                                        | 0.5 ml (1 dose)           | 1 single dose vial (1 dose)          |
| EU/1/20/1507/022 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | vial (glass)                                                        | 0.5 ml (1 dose)           | 10 single dose vials (10 doses)      |
| EU/1/20/1507/023 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in                     | 0.5 ml (1 dose)           | 1 pre-filled syringe (1 dose)        |
| EU/1/20/1507/024 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | a blister pre-filled syringe (cyclic olefin copolymer) in a blister | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses)    |
| EU/1/20/1507/025 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a tray              | 0.5 ml (1 dose)           | 1 pre-filled syringe (1 dose)        |
| EU/1/20/1507/026 | Spikevax JN.1     | -- 6       | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a tray              | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses)    |

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging                                       | Content (concentration)   | Pack size                            |
|------------------|-------------------|------------|--------------------------|---------------------------|-----------------------------------------------------------|---------------------------|--------------------------------------|
| EU/1/20/1507/027 | Spikevax XBB.1.5  | --5        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a blister | 0.25 ml (1 dose)          | 1 pre-filled syringe (1 dose)        |
| EU/1/20/1507/028 | Spikevax XBB.1.5  | --5        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a blister | 0.25 ml (1 dose)          | 10 pre-filled syringes (10 doses)    |
| EU/1/20/1507/029 | Spikevax XBB.1.5  | --5        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a tray    | 0.25 ml (1 dose)          | 1 pre-filled syringe (1 dose)        |
| EU/1/20/1507/030 | Spikevax XBB.1.5  | --5        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a tray    | 0.25 ml (1 dose)          | 10 pre-filled syringes (10 doses)    |
| EU/1/20/1507/031 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | vial (glass)                                              | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses) |
| EU/1/20/1507/032 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | vial (cyclic olefin polymer)                              | 2.5 ml (5 or 10 doses)    | 10 multidose vials (50 or 100 doses) |
| EU/1/20/1507/033 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a blister | 0.5 ml (1 dose)           | 1 pre-filled syringe (1 dose)        |

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging                                           | Content (concentration)   | Pack size                         |
|------------------|-------------------|------------|--------------------------|---------------------------|---------------------------------------------------------------|---------------------------|-----------------------------------|
| EU/1/20/1507/034 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in               | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses) |
| EU/1/20/1507/035 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | a blister pre-filled syringe (cyclic olefin copolymer) in     | 0.5 ml (1 dose)           | 1 pre-filled syringe (1 dose)     |
| EU/1/20/1507/036 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in a tray        | 0.5 ml (1 dose)           | 10 pre-filled syringes (10 doses) |
| EU/1/20/1507/037 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | pre-filled syringe (cyclic olefin copolymer) in               | 0.25 ml (1 dose)          | 1 pre-filled syringe (1 dose)     |
| EU/1/20/1507/038 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | a blister pre-filled syringe (cyclic olefin copolymer) in     | 0.25 ml (1 dose)          | 10 pre-filled syringes (10 doses) |
| EU/1/20/1507/039 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | a blister pre-filled syringe (cyclic olefin copolymer) in     | 0.25 ml (1 dose)          | 1 pre-filled syringe (1 dose)     |
| EU/1/20/1507/040 | Spikevax LP.8.1   | --7        | Dispersion for injection | Intramuscular use         | a tray pre-filled syringe (cyclic olefin copolymer) in a tray | 0.25 ml (1 dose)          | 10 pre-filled syringes (10 doses) |

<div style=\"page-break-after: always\"></div>

```
--¹ One dose (0.5 mL) contains 100 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). One dose (0.25 mL) contains 50 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles) Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). --² One dose (0.5 mL) contains 50 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). One dose (0.25 mL) contains 25 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). --³ One dose (0.5 mL) contains 25 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles) and 25 micrograms of imelasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). One dose (0.25 mL) contains 12.5 micrograms of elasomeran and 12.5 micrograms of imelasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). Imelasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron BA.1). --⁴ One dose (0.5 mL) contains 25 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles) and 25 micrograms of davesomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). One dose (0.25 mL) contains 12.5 micrograms of elasomeran and 12.5 micrograms of davesomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original).
```

<div style=\"page-break-after: always\"></div>

Davesomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron BA.4-5). The S proteins of the SARS-CoV-2 Omicron variant lineages BA.4 and BA.5 are identical. -- 5 One dose (0.5 mL) contains 50 micrograms of andusomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). One dose (0.25 mL) contains 25 micrograms of andusomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). Andusomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5). -- 6 One dose (0.5 mL) contains 50 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). One dose (0.25 mL) contains 25 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). SARS-CoV-2 JN.1 mRNA is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (JN.1). -- 7 One dose (0.5 mL) contains 50 micrograms of SARS-CoV-2 LP.8.1 mRNA, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). One dose (0.25 mL) contains 25 micrograms of SARS-CoV-2 LP.8.1 mRNA, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). SARS-CoV-2 LP.8.1 mRNA is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (LP.8.1).